Skip to content

Communication Skills Intervention to Promote Transition Into Survivorship

Communication Skills Intervention to Promote Transition Into Survivorship

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01483664
Enrollment
314
Registered
2011-12-01
Start date
2011-11-01
Completion date
2026-11-01
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-cell Lymphoma, Hodgkin's Lymphoma

Keywords

patient outcomes, Survivorship, Communication Skills, Communication strategies, Physicians communication, 11-180

Brief summary

The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.

Interventions

None listed

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER
M.D. Anderson Cancer Center
CollaboratorOTHER
Maimonides Medical Center
CollaboratorOTHER
H. Lee Moffitt Cancer Center and Research Institute
CollaboratorOTHER
Rutgers University
CollaboratorOTHER
Tampa General Hospital
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
Monash University
CollaboratorOTHER
Weill Cornell Medical College in Qatar
CollaboratorOTHER
New York Presbyterian Brooklyn Methodist Hospital
CollaboratorOTHER
San Francisco State University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Physicians: * who treat patients with DLBCL and HD as per self report Patients of Physicians: * have a new diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician treated with curative intent. For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment. For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment. * be at least 18 years old * speak English well enough, in the judgment of the consenting professional, to be able to understand all aspects of the study, provide informed consent, and be able to complete all study measures.

Exclusion criteria

Physicians: * who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report Patients of Physicians: * show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study. * as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study. For Part 2 ONLY (longitudinal phase): * those who consented to part 1, consult recording, of the study.

Design outcomes

Primary

MeasureTime frame
impact on patient outcomes of targeted physician communication skills training3 years

Secondary

MeasureTime frameDescription
impact of a targeted CST intervention on the physicians3 yearsuse of strategies, tasks and skills about transitioning lymphoma patients from the end of primary treatment to survivorship.
describe communication during doctor-patient visits during the patients' first three years of survivorship3 years(MSKCC and MD Anderson baseline data only) The study team will look for qualitative themes to better understand the content of these conversations and the need for survivorship care planning. Half of these recordings were with MSKCC patients and physicians and half were with MD Anderson patients and physicians.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPatricia Parker, PhD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026